Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leriglitazone in pediatric male patients with cerebral X-linked adrenoleukodystrophy before HSCT
2024-513774-21-00Phase 3Completed
- Sponsor
- Minoryx Therapeutics
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of leriglitazone in X-linked adrenoleukodystrophy (X-ALD), sponsored by Minoryx Therapeutics. Primary endpoint: Arrested disease at Visit 12. Started Sep 2019; status: completed.
02
Drugs
leriglitazone
03
Conditions
X-linked adrenoleukodystrophy (X-ALD)
Beyond the preview
Go deeper on 2024-513774-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513774-21-00.